References in periodicals archive ?
Moxatag is the first and only approved once-daily formulation of the widely-used antibiotic amoxicillin.
United Kingdom-based Vernalis has acquired the US rights of Moxatag amoxicillin extended-release tablets from Pragma Pharmaceuticals, it was reported yesterday.
"Moxatag samples will be a key element of our nationwide launch to health care professionals in March 2009," MiddleBrook president and chief executive officer John Thievon said.
MiddleBrook has already made progress in this therapeutic class with Moxatag, the first and only FDA-approved once-daily amoxicillin.
"As the first and only once-daily amoxicillin therapy approved for marketing in the United States, we believe Moxatag represents a major advance for patients and doctors seeking safe, effective, and convenient treatment options for strep throat," says Edward Rudnic, PhD, president and CEO of MiddleBrook.
* Special Considerations: Moxatag is contraindicated in patients with known hypersensitivity to amoxicillin or other penicillin agents; serious anaphylactic reactions are possible.
Moxatag was "'noninferior'" to penicillin VK in terms of bacterial eradication of S.
Treatment-related or probably-treatment-related adverse events reported in a phase III trial of Moxatag included vulvovaginal mycotic infections, diarrhea, nausea, vomiting, abdominal pain, and headache.
6 October 2015 - UK-based drugmaker Vernalis plc (LSE: VER) has acquired US rights to Moxatag (amoxicillin extended-release tablets) from Pragma Pharmaceuticals, LLC (Pragma), the company's US-based commercialisation arm, Vernalis Therapeutics Inc., said.
Target: US rights to Moxatag (amoxicillin extended-release tablets)
M2 PHARMA-August 19, 2014-Pragma Pharmaceuticals plans to re-launch Moxatag 775mg
MiddleBrook has entered an agreement with DoctorDirectory.com Inc., its promotion partner for Moxatag (amoxicillin), and plans to use online education and promotions to reach prescribers with sales and marketing messages for the drug.
"This commercial line of credit will provide us with greater financial flexibility to support our business objectives and commercialize Moxatag," declares Dave Becker, MiddleBrook's executive vice president and chief financial officer.